Hematologic Risk Factors for the Development of Retinopathy of Prematurity-A Retrospective Study.
Gabriela Ildikó ZondaRaluca MogosAlina-Sînziana Melinte-PopescuAna-Maria AdamValeriu HaraborDragos NemescuDemetra Gabriela SocolovAnamaria HaraborMarian Melinte-PopescuMaura-Adelina HincuIngrid Andrada VasilacheAlexandru CărăuleanuGigi AdamLuminita PăduraruPublished in: Children (Basel, Switzerland) (2023)
(1) Background: Retinopathy of prematurity (ROP) can cause severe visual impairment or even blindness. We aimed to assess the hematological risk factors that are associated with different stages of ROP in a cohort of preterm newborns, and to compare the clinical characteristics and therapeutic interventions between groups. (2) Methods: This retrospective study included 149 preterm newborns from a tertiary maternity hospital in Romania between January 2018 and December 2018, who were segregated into: Group 1 (with ROP, n = 59 patients), and Group 2 (without ROP, n = 90 patients). The patients that were affected by ROP were subsequently divided into the following subgroups: Subgroup 1 (Stage 1, n = 21), Subgroup 2 (Stage 2, n = 35), and Subgroup 3 (Stage 3, n = 25). The associations were analyzed using multivariate logistic regression and sensitivity analysis. (3) Results: Platelet mass indexes (PMI) that were determined in the first, seventh, and tenth days of life were significantly associated with Stage 1 ROP. PMI determined in the first day of life was also significantly associated with Stage 2 ROP. The sensitivity and specificity of these parameters were modest, ranging from 44 to 57%, and 59 to 63%. (4) Conclusions: PMI has a modest ability to predict the development of ROP.